New antibody combo shows promise in Hard-to-Treat cancers
NCT ID NCT04886271
First seen Apr 30, 2026 · Last updated May 24, 2026 · Updated 3 times
Summary
This study tested a new drug called HX009 in 20 adults with advanced solid tumors that had not responded to standard treatments. HX009 is a bifunctional antibody designed to help the immune system attack cancer cells. The main goal was to see if the drug could shrink tumors, and researchers also monitored side effects and how long any response lasted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, China
Conditions
Explore the condition pages connected to this study.